Identificador persistente para citar o vincular este elemento: https://accedacris.ulpgc.es/handle/10553/141746
Campo DC Valoridioma
dc.contributor.authorMacías Verde, David Armandoen_US
dc.contributor.authorBurgos-Burgos, Javieren_US
dc.contributor.authorLara, Pedro C.en_US
dc.date.accessioned2025-06-30T08:45:55Z-
dc.date.available2025-06-30T08:45:55Z-
dc.date.issued2025en_US
dc.identifier.issn2072-6694en_US
dc.identifier.otherWoS-
dc.identifier.urihttps://accedacris.ulpgc.es/handle/10553/141746-
dc.description.abstractBackground: Patients bearing large-volume, bulky primary or relapsed tumors, are usually referred to palliative low-dose radiotherapy with very poor results. Lattice Radiation Therapy (LRT) is able to produce a high number of high-dose foci or vortexes (multiple SBRT treatments), separated by low-dose zones (valleys). Treatment planning on vortex placing, valley definition, and dose administered depends on individual decisions of the treating team. The aim of our study is to assess for the first time the possibility of a dense fractionated LRT within the target volume. Methods: A total of 22 treatments in 20 patients were performed in the frame of a prospective observational study of fractionated LRT ongoing in our institution. According to our aim of achieving dense LRT, no GTV contraction was considered to create the LRTV (GTV is equal to LRTV). The vortexes were segmented as 1 cm diameter at a 1.5 cm vortex-to-vortex distance. Dose prescription to the vortexes per fraction was 12 Gy. Results: The vortex/LRTV ratio was 7.38 +/- 2.13% (3.4-10.40%, median 7.60%). Mean dose to the vortex volume was 11.90 +/- 0.09 Gy (11.70-12.10 Gy, median 11.90 Gy). Mean dose administered to the valley volume was 8.29 +/- 0.70 (7.05-9.51 Gy, median 8.29 Gy). Valley/vortex (peak) dose ratio (VPDR) was 69.40 +/- 6.02% (59.00-79.80%, median 69.70%). The mean peripheral tumor dose was 5.11 +/- 0.8710 Gy (3.16-6.78 Gy, median 5.18 Gy). Conclusions: Our dense LRT schedule fulfilled most of the recommended guidelines for LRT, increasing the high dose points without risking the dose to the surrounding tissues. Further analysis of feasibility and safety are needed to secure the clinical relevance of our proposed protocol.en_US
dc.languageengen_US
dc.relation.ispartofCancers (Basel)en_US
dc.sourceCancers, [ISSN 2072-6694] v. 17 (12), (Junio 2025)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320101 Oncologíaen_US
dc.subject320111 Radiologíaen_US
dc.subject.otherPhase-I Trialen_US
dc.subject.otherLite Sabr M1en_US
dc.subject.otherRadiotherapyen_US
dc.subject.otherLattice Radiation Radiotherapyen_US
dc.subject.otherLrten_US
dc.subject.otherSfrten_US
dc.subject.otherFractionateden_US
dc.subject.otherDenseen_US
dc.titleAutomated Clinical Dosimetry Planning of Dense Lattice Radiation Therapyen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/cancers17122048en_US
dc.identifier.isi001514701000001-
dc.identifier.eissn2072-6694-
dc.identifier.issue12-
dc.relation.volume17en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.description.numberofpages12en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Macias-Verde, D-
dc.contributor.wosstandardWOS:Burgos-Burgos, J-
dc.contributor.wosstandardWOS:Lara, PC-
dc.date.coverdateJunio 2025en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr1,391
dc.description.jcr4,5
dc.description.sjrqQ1
dc.description.jcrqQ1
dc.description.miaricds10,6
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.fullNameMacías Verde, David Armando-
Colección:Artículos
Vista resumida

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.